The aim was to determine in circulating mononuclear cells from patients with erectile dysfunction (ED), the level of expression of endothelial nitric oxide synthase (eNOS), soluble guanylate cyclase (sGC) b 1 -subunit and phosphodiesterase type-V (PDE-V). Peripheral mononuclear cells from nine patients with ED of vascular origin and nine patients with ED of neurological origin were obtained. Fourteen age-matched volunteers with normal erectile function were used as control. Reduction in eNOS protein was observed in the mononuclear cells from patients with ED of vascular origin but not in those from neurological origin. Although sGC b 1 -subunit expression was increased in mononuclear cells from patients with ED, the sGC activity was reduced. However, only the patients with ED of vascular origin showed an increased expression of PDE-V. This work shows for the first time that, independently of the aetiology of ED, the expression of sGC b 1 -subunit was increased in circulating mononuclear cells; however, the expression of both eNOS and PDE-V was only modified in the circulating mononuclear cells from patients with ED of vascular origin.
Introduction
Penile erection is regulated by the relaxation of arteriolar and trabecular smooth muscle cells which it is mediated by the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) pathway. Nitric oxide is a nonadrenergic-noncholinergic neurotransmitter that is released from postgangliomic parasympathetic (cholinergic) nerves in the penis and NO is also released from the endothelium. [1] [2] [3] Both neuronal NOS (nNOS) isoform and the endothelial NOS (eNOS) participate in cavernosal relaxation.
Independently of the NO generating systems, a reduction in the NO-induced vasorelaxation could also results from impaired downstream signaling in the vascular smooth muscle cells. Nitric oxide stimulates soluble guanylate cyclase (sGC) and the activation of sGC elevates intracellular levels of cGMP, resulting in relaxation of the corporal smooth muscle, dilatation of the penile arteries, arterioles and sinusoids, and finally, increased arterial inflow and passive compression of the penile venous outflow. 4, 5 Soluble guanylate cyclase is a heterodimer composed of a large (a 1 ) and a small (b 1 ) subunits and both subunits are required to produce cGMP. 6 Cyclic guanosine monophosphate is catabolized by phosphodiesterase type-V (PDE-V) that it has been identified in human cavernous tissue and plays a relevant role in penile erection. However, it is now known that other tissues expressed PDE-V. 7 Leukocytes also produce NO by an eNOS-like NOS and contain sGC. 8, 9 However, despite of leukocytes are more accessible cells than the vascular cells contained in the corpus cavernosum, the ability of the leukocytes to express eNOS, sGC and PDE-V in patients with erectile dysfunction (ED) has not been explored. Therefore, the aim of the present study was to test if mononuclear cells from patients with ED of vascular and neurological origin have modified the level of expression of either eNOS, sGC and PDE-V.
Materials and methods

Study protocol
Male ED patients ranging in age from 33 to 81 years (mean 55.4) were enrolled in the study. All patients were initially evaluated by taking a detailed sexual and medical history and diagnosed of ED as evaluated by the IIEF standardized questionnaire. 10 Six patients did not achieve a full rigid erection, three patients showed a short-length full erection and nine patients showed lack of erection. Patients were divided into two categories according to the echo-Doppler analysis after intravenous prostaglandin E 1 infusion. The vascular ED group included patients (n ¼ 9; mean age 55.6 years) that showed alterations to prostaglandin E 1 , a vasodilator, during the echo-Doppler examination based on the peak systolic velocity and resistance index. In this group, the patients also showed previous history of vascular risk factors. In this regard, one patient had history of hypertension, two had hyperlipemia, two had ischemic heart disease associated with hyperlipemia and four patients had not vascular risk factors.
The second group was the neurological ED group that included patients (n ¼ 9; mean age 56.6 years) with ED of neurological origin each of whom achieved a full rigid erection after prostaglandin E 1 injection. This group included two patients with radical prostatectomy, one patient with cortical atrophy, two patients with diabetes and four patients with peripheral neuropathy. Patients taking PDE-V inhibitors in the 6 months previous to the study were excluded. Fourteen age-matched (mean age 54.7 years) with normal erectile function were used as reference for control values. These agematched patients were going to be operated of Cryptorchidism, Varicocele and Hydrocele. All subjects gave fully informed consent and the study was approved by the local Ethic Committee. The study was blind for the investigators that determined the molecular parameters and analyzed the results.
Blood samples were drawn from a peripheral vein. Mononuclear cells were isolated by Ficoll-Hypaque centrifugation and the layer containing leukocytes and lymphocytes was removed and immediately frozen at À801C for molecular determinations.
Determination of endothelial nitric oxide synthase, soluble guanylate cyclase b 1 subunit and phosphodiesterase type-V The expression of eNOS, sGC b 1 -subunit and PDE-V proteins was analyzed by Western blot as described. 11, 12 In brief, mononuclear cells were resuspended and solubilized in Laemmli buffer containing 2-mercaptoethanol. 13 The proteins obtained were separated in denaturing SDS/10% polyacrylamide gels. Equal amounts of proteins (10 mg per lane) estimated by bicinchonic acid reagent (Pierce Rockford, IL, USA) were loaded. Western blot analysis was performed with a monoclonal antibody against eNOS (1:1500 Transduction Laboratories, Lexington, UK), sGC b 1 -subunit (1:1500 Alexis Laboratories, San Diego, CA, USA) or PDE-V (1:2500 Calbiochem, La Jolla, CA, USA). Specific eNOS, sGC b-subunit and PDE-V proteins were detected by enhanced chemoluminiscense (ECL, Amersham Corp) and evaluated by densitometry (Molecular Dynamics). Prestained protein markers (Sigma) were used for molecular mass determinations.
Determination of soluble guanylate cyclase activity 5 Â 10 6 mononuclear cells per tube were incubated at 371C in RPMI medium containing 0.025% bovine serum albumin for 15 min. To investigate the functional activity of sGC, mononuclear cells were incubated in the presence and in the absence of a NO-donor, sodium nitroprusside (10 À5 mol/l; SNP) and a PDE inhibitor, 3-isobutil-1-methylxanthine (10 À4 mol/l; IBMX) that prevent cGMP breakdown. Afterwards, mononuclear cells were lysed in 1 mol/l ClH in ethanol. After having been mixed, the homogenates were centrifuged (12 000 g, 15 min at 41C) and the supernatants were recovered and dried by speed-vac. Cyclic guanosine monophosphate was measured in acetylated samples with a kit from Amersham International as reported. 14 
Statistical analysis
Results are expressed as mean7s.e.m. Comparisons were performed by ANOVA. Bonferroni's correction for multiple comparisons was used to determine the level of significance of the P-value. Po0.05 was considered significant.
Results
Endothelial nitric oxide synthase expression in mononuclear cells A significant reduction in the level of eNOS protein expressed in mononuclear cells obtained from patients with ED was observed compared with those from age-matched controls (Figure 1 ).
When ED patients were divided as ED of vascular and neurological origin, only mononuclear cells from the vascular ED patients showed a significant reduction of the eNOS protein level compared with those from age-matched controls (Figure 2 ). Endothelial nitric oxide synthase expression also tended to be reduced in the mononuclear cells from patients with ED of neurological origin although it did not reach statistical significance 
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The expression of PDE-V was increased in the mononuclear cells from patients with ED ( Figure 5) . However, the expression of PDE-V was only increased in the patients with ED of vascular origin ( Figure 6 ). The expression of PDE-V in the mononuclear cells from patients with ED of neurological origin was very similar to that observed in the mononuclear cells from age-matched controls (Figure 6 ).
Cyclic guanosine monophosphate levels in mononuclear cells
Basal cGMP levels in mononuclear cells from ED patients were found reduced compared with those from age-matched controls (control: 19.573; ED: 13.572 fmol/5 Â 10 6 cells; Po0.05). The basal cGMP levels were reduced in mononuclear cells from patients with ED of neurological origin (Table 1 ). Mononuclear cells from ED patients of vascular origin also showed a reduced basal cGMP levels compared with control although it did not reach statistical signification (Table 1) . Stimulation of mononuclear cells with the NO-donor, SNP (10 À5 mol/l) increased cGMP levels in mononuclear cells from both controls and ED patients of vascular and neurological origin (Table 1) . However, the cGMP levels observed in SNP (10 À5 mol/l)-stimulated mononuclear cells from patients of neurological origin were lower than that observed in 10 À5 mol/l SNP-stimulated mononuclear cells from ED patients of vascular origin (Table 1) .
We further analyzed the activity of sGC by stimulating sGC with SNP and inhibiting PDE with IBMX (10 À4 mol/l). As shown in Table 1 , the blockade of PDE by IBMX enhanced the activity of sGC induced by SNP in the mononuclear cells from all the experimental groups although sGC activity remained higher in controls than in ED patients (Table 1 ). In addition, cGMP levels in SNP þ IBMXincubated mononuclear cells was also higher in ED patients of vascular origin than those from neurological origin (Table 1) .
Discussion
Nitric oxide produced by the neuronal NOS isoform contained in the nerve fibers has been identified as Mononuclear cells and erectile dysfunction PJ Mateos-Cáceres et al an important mediator of penile erection. 15 Recent evidences have suggested that the eNOS isoform has also a relevant role in penile erection. 16 Erectile dysfunction may causes endothelial dysfunction. An important concept related to endothelial dysfunction is that it is a systemic disease. For example, it has been demonstrated correlation between endothelial dysfunction in the coronary arteries and in the forearm circulation. 17 Moreover, Foresta et al. 18 have recently demonstrated that the number of circulating endothelial progenitor cells was reduced in ED patients as a sign of systemic endothelial dysfunction. The activity of leukocytes is increased by the endothelial dysfunction. Since leukocytes contain the entire machinery of the NO/ cGMP system, we analyzed whether ED may be reflected in modifications of the NO/cGMP system in circulating leukocytes.
Circulating mononuclear cells from patients with ED of vascular origin showed a reduced of eNOS protein expression. However, the level of eNOS protein expressed in mononuclear cells from patients with ED of neurological origin was not statistically modified, although tended to be diminished with respect to that of age-matched control.
The mechanisms underlying the downregulation of eNOS protein in mononuclear cells from ED patients of vascular origin were not established in the present study. In vitro studies have shown that inflammation, and more particularly cytokines are intimately involved in the downregulation of eNOS protein in both the endothelium and leukocytes. 19, 20 In this regard, a recent review from Jeremy et al. 21 and Giugliano et al. 22 have suggested a relationship between ED and inflammation. The expression of eNOS protein seem to be preserved in the mononuclear cells from the patients with ED of neurological origin, which could be related to a lower production of inflammatory mediators than in the patients with ED of vascular origin. Another possibility may be that the level of other eNOS regulatory factors, such as vascular endothelial growth factor which it has been demonstrated to restore ED, 23 could be different between patients with ED of vascular and neurological origin. Further studies are warranted to clarify these hypotheses.
Independently of the level of expression of the eNOS protein, the sGC, the main receptor for NO, was upregulated in mononuclear cells obtained from ED patients. The upregulation of the sGC b 1 -subunit in mononuclear cells was independent of the aetiological origin of the ED.
We have not determined the precise mechanisms by which sGC may be upregulated in mononuclear cells from patients with ED. Indeed, it is not well known the mediators involved in the regulation of the expression of sGC. In this regard, Hussain et al. 24 have showed that NO reduction upregulated sGCcGMP signaling in mouse thoracic aorta. Therefore, the reduced expression of eNOS protein found in the mononuclear cells from ED patients could be involved in the upregulation of the sGC b 1 -subunit. Further studies are needed to explore it.
Soluble guanylate cyclase is an heterodimer composed of a large (a 1 ) and a small b 1 subunits and both sGC subunits are required for the enzymatic activity of sGC. 6 Therefore, upregulation of the sGC b 1 -subunit may increase the ability of this enzyme to produce cGMP. However, a reduced cGMP production was found when mononuclear cells from the patients with ED were stimulated with the exogenous NO-donor, SNP. Initially, it seems to be a paradoxical result since the upregulation of sGC was accompanied with cGMP reduction. Therefore, we determined the level of expression of PDE-V in the mononuclear cells. Western blot experiments showed that mononuclear cells expressed PDE-V. Previously, Tenor et al. 25 and Sarfeti et al. 26 have showed, by functional experiments, that lymphocytes contain PDE-V activity. We showed here for the first time the expression of PDE-V by Western blot in human mononuclear cells.
Phosphodiesterase type-V expression was only found upregulated in mononuclear cells from patients with ED of vascular origin. Therefore, we determined the activity of sGC in the mononuclear cells by stimulating sGC with SNP and blocking the cGMP catabolism with IBMX, an inhibitor of PDE activities. These experiments showed that sGC activity was reduced in the mononuclear cells from ED patients compared with control. Moreover, sGC activity was significatively lower in mononuclear cells from ED patients of neurological origin than in those from vascular origin. Taken together, these findings suggest that, independently of eNOS protein expression, the reduction of cGMP production in mononuclear cells from the ED patients of vascular origin may be related to both upregulation of PDE-V and reduction in the sGC activity, whereas in the patients of neurological origin may be attributed to a decreased sGC activity.
As limitations of the study, the present experimental design does not allow us to determine the implication of the changes observed in the expression of enzymes involved in the NO-cGMP generating system on the functionality of mononuclear cells of ED patients.
In summary, the present work shows for the first time that, independently of the aetiological origin of the ED, sGC b 1 -subunit is upregulated in circulating mononuclear cells from patients with ED whereas PDE-V expression was only modified in the patients with ED of vascular origin. A more reliable biomarker associated with ED was the evaluation of the sGC b 1 -subunit than both eNOS and PDE-V expression. Therefore, the better understanding of the regulatory mechanisms of sGC may lead to new strategies in the prevention and treatment of ED.
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